Takayasu Arteritis
48
13
14
18
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.2%
2 terminated out of 48 trials
90.0%
+3.5% vs benchmark
23%
11 trials in Phase 3/4
11%
2 of 18 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 18 completed trials
Clinical Trials (48)
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Upadacitinib for Refractory Takayasu Arteritis
Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients
Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
VCRC Tissue Repository
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis
Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)
Effect of Pirfenidone on TA Fibrosis
Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy Controls
Surgery Benefits Takayasu Arteritis With Stenosis in the Descending Aorta
Turkish Adaptation of the VascuQoL-6 Quality of Life Scale
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
Takayasu Arteritis Clinical Trial in China
Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Baricitinib for Refractory Takayasu Arteritis
A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis